Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2016.
Shareholder Update April 2016
In this issue:
> Message from the CEO
> Adama licenses Priostar® for 2,4-D
> DEPTM cabazitaxel shows superior performance
> Starpharma's Targeted DEPTM conjugates - compelling results in an area of high interest
> AstraZeneca selects second DEPTM candidate
> Starpharma long standing collaborator ranked 4th in the world
> Starpharma signs licence with Aspen for commercialisation of VivaGel® BV in Australia and New Zealand
> MOU for VivaGel® condom in China
> Half-year financial results
> Bio-Europe® conference
Download: Shareholder Update April 2016 (pdf file, 1MB)
Starpharma to present at Bio-Europe conference
Starpharma today announced that it will present this week at the Bio-Europe® conference in Stockholm. At the conference Starpharma will also be conducting partnering discussions with pharmaceutical companies for VivaGel® BV, DEPTM and other parts of Starpharma’s portfolio.
DEP cabazitaxel shows complete and sustained tumour regression in breast cancer model
Starpharma today announced further efficacy results of its most recent DEP™ candidate, DEP™ cabazitaxel, in a human breast cancer model. These data will be presented along with an overview of Starpharma’s DEP™ platform at the BioEurope Spring 2016 conference in Stockholm later this week.